11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) experience disease progression during treatment due to brain metastases. Despite anecdotal reports of EGFR-TKIs providing benefit in some patients with EGFRm NSCLC brain metastases, there is a clinical need for novel EGFR-TKIs with improved efficacy against brain lesions.

          Related collections

          Author and article information

          Journal
          Clin. Cancer Res.
          Clinical cancer research : an official journal of the American Association for Cancer Research
          American Association for Cancer Research (AACR)
          1078-0432
          1078-0432
          Oct 15 2016
          : 22
          : 20
          Affiliations
          [1 ] iMED Oncology, AstraZeneca, Macclesfield, United Kingdom. Darren.Cross@astrazeneca.com pbdmpk@gmail.com.
          [2 ] iMED Oncology, AstraZeneca, Cambridge, United Kingdom.
          [3 ] Asia and Emerging Markets iMED, AstraZeneca, Shanghai, China.
          [4 ] Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
          [5 ] National Taiwan University Hospital, Taipei City, Taiwan.
          [6 ] Global Medicines Development, AstraZeneca, Macclesfield, United Kingdom.
          [7 ] iMED Oncology, AstraZeneca, Macclesfield, United Kingdom.
          [8 ] AstraZeneca, Cambridge, United Kingdom.
          [9 ] AstraZeneca Translational Science Centre, Stockholm, Sweden. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
          [10 ] Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
          [11 ] iMED Oncology, AstraZeneca, Gatehouse Park, Waltham, Massachusetts.
          [12 ] Dana-Farber Cancer Institute, Boston, Massachusetts.
          [13 ] iMED Oncology, AstraZeneca, Cambridge, United Kingdom. Darren.Cross@astrazeneca.com pbdmpk@gmail.com.
          Article
          1078-0432.CCR-16-0399
          10.1158/1078-0432.CCR-16-0399
          27435396

          Comments

          Comment on this article